MBC Surgery & Treatment

Posters

MyPathologyReport.ca – A pathology education resource for patients

Promising drugs, from The Storm Riders

2018 FDA Oncology Drug Approvals With Canadian Approvals In the Comments

NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases

CAR T Cell Therapy

IBRANCE

Approved Health Canada Indications and Clinical Use for Ibrance
• In combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
• In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor  2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy. Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist.

When the Patient Is the Loser (American Insurer Article)

Memorial Sloan Kettering Cancer Center

Provides a database of herbs, botanicals and supplements

Close Menu